NovoCure (NVCR) Competitors $14.35 +0.19 (+1.34%) Closing price 04:00 PM EasternExtended Trading$14.36 +0.01 (+0.03%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVCR vs. IRTC, BLCO, GKOS, TMDX, NVST, SLNO, LIVN, WRBY, INSP, and EYEShould you be buying NovoCure stock or one of its competitors? The main competitors of NovoCure include iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Glaukos (GKOS), TransMedics Group (TMDX), Envista (NVST), Soleno Therapeutics (SLNO), LivaNova (LIVN), Warby Parker (WRBY), Inspire Medical Systems (INSP), and National Vision (EYE). These companies are all part of the "medical equipment" industry. NovoCure vs. Its Competitors iRhythm Technologies Bausch + Lomb Glaukos TransMedics Group Envista Soleno Therapeutics LivaNova Warby Parker Inspire Medical Systems National Vision NovoCure (NASDAQ:NVCR) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk. Which has more volatility & risk, NVCR or IRTC? NovoCure has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Does the media refer more to NVCR or IRTC? In the previous week, iRhythm Technologies had 11 more articles in the media than NovoCure. MarketBeat recorded 13 mentions for iRhythm Technologies and 2 mentions for NovoCure. iRhythm Technologies' average media sentiment score of 0.42 beat NovoCure's score of 0.27 indicating that iRhythm Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iRhythm Technologies 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend NVCR or IRTC? NovoCure currently has a consensus price target of $27.50, indicating a potential upside of 91.64%. iRhythm Technologies has a consensus price target of $173.17, indicating a potential downside of 3.26%. Given NovoCure's higher possible upside, equities analysts plainly believe NovoCure is more favorable than iRhythm Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovoCure 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38iRhythm Technologies 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.79 Which has preferable earnings & valuation, NVCR or IRTC? iRhythm Technologies has lower revenue, but higher earnings than NovoCure. iRhythm Technologies is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovoCure$605.22M2.65-$168.63M-$1.56-9.20iRhythm Technologies$591.84M9.72-$113.29M-$2.93-61.09 Is NVCR or IRTC more profitable? iRhythm Technologies has a net margin of -14.06% compared to NovoCure's net margin of -27.13%. NovoCure's return on equity of -47.74% beat iRhythm Technologies' return on equity.Company Net Margins Return on Equity Return on Assets NovoCure-27.13% -47.74% -13.79% iRhythm Technologies -14.06%-90.03%-8.52% Do insiders and institutionals have more ownership in NVCR or IRTC? 84.6% of NovoCure shares are held by institutional investors. 5.5% of NovoCure shares are held by insiders. Comparatively, 1.1% of iRhythm Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryiRhythm Technologies beats NovoCure on 10 of the 17 factors compared between the two stocks. Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCR vs. The Competition Export to ExcelMetricNovoCureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.58B$3.35B$6.11B$10.56BDividend YieldN/A2.29%5.69%4.75%P/E Ratio-9.2021.5785.4827.60Price / Sales2.65476.51624.19239.62Price / CashN/A47.1237.9261.55Price / Book4.3110.1413.136.76Net Income-$168.63M-$52.31M$3.30B$275.88M7 Day Performance2.65%6.72%5.29%3.72%1 Month Performance13.89%15.01%9.94%10.22%1 Year Performance-2.11%29.34%87.78%35.86% NovoCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCRNovoCure4.2279 of 5 stars$14.35+1.3%$27.50+91.6%-3.1%$1.58B$605.22M-9.201,488Analyst ForecastIRTCiRhythm Technologies1.1401 of 5 stars$175.74+0.1%$172.17-2.0%+194.3%$5.65B$591.84M-59.982,000Analyst ForecastBLCOBausch + Lomb1.948 of 5 stars$14.87-2.2%$15.60+4.9%-22.0%$5.26B$4.79B-19.0613,500News CoverageAnalyst ForecastGKOSGlaukos4.4502 of 5 stars$86.64-0.9%$122.00+40.8%-33.3%$4.97B$432.95M-52.51780Analyst ForecastGap UpTMDXTransMedics Group2.7896 of 5 stars$113.93-1.5%$125.40+10.1%-14.1%$3.88B$441.54M59.03210Analyst DowngradeNVSTEnvista3.769 of 5 stars$20.64-1.0%$20.92+1.4%+11.8%$3.43B$2.51B64.5012,300Analyst ForecastSLNOSoleno Therapeutics4.4004 of 5 stars$58.45-1.3%$115.09+96.9%+30.4%$3.11BN/A-14.1230Analyst ForecastLIVNLivaNova2.3147 of 5 stars$52.63-1.4%$59.71+13.5%-1.0%$2.87B$1.25B-13.532,900Analyst ForecastWRBYWarby Parker1.8567 of 5 stars$25.41-3.1%$24.75-2.6%+50.6%$2.67B$771.32M-362.953,780News CoveragePositive NewsAnalyst ForecastINSPInspire Medical Systems4.8182 of 5 stars$76.36-0.3%$154.43+102.2%-62.9%$2.26B$802.80M44.141,246Analyst ForecastEYENational Vision2.6095 of 5 stars$28.15-2.5%$24.73-12.2%+169.4%$2.23B$1.82B-156.3913,411Positive NewsAnalyst Forecast Related Companies and Tools Related Companies iRhythm Technologies Alternatives Bausch + Lomb Alternatives Glaukos Alternatives TransMedics Group Alternatives Envista Alternatives Soleno Therapeutics Alternatives LivaNova Alternatives Warby Parker Alternatives Inspire Medical Systems Alternatives National Vision Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVCR) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredHow to profit from the AI maniaPorter Stansberry says the AI boom’s next trillion-dollar winners won’t be chatbots or Big Tech — but the over...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
